Application of DT3C Protein in ADC Antibody Internalization Assay

I. Introduction

Antibody-drug conjugates (ADCs) achieve precise tumor cell killing by conjugating highly cytotoxic drugs with monoclonal antibodies. In ADC drug development, the internalization efficiency of antibodies after binding to target antigens is a key determinant of therapeutic efficacy. Traditional antibody internalization assays face limitations such as complex procedures, long cycles, or inability to accurately simulate ADC molecular characteristics. DT3C protein, a recombinant fusion protein composed of the catalytic domain of diphtheria toxin and the C1, C2, C3 domains of streptococcal protein G, provides an efficient tool for in vitro assessment of antibody internalization efficiency. This article systematically elaborates on the structural features, working principles, and application value of DT3C protein in ADC antibody screening.

II. Biological Basis of ADC Internalization

The mechanism of ADC drugs relies on antibody-mediated targeted delivery and internalization. After conjugation via linkers, the antibody portion specifically recognizes tumor cell surface antigens, forming antigen-antibody complexes that undergo endocytosis. In acidic intracellular environments or through lysosomal protease action, linkers cleave to release cytotoxic payloads that induce tumor cell apoptosis by inhibiting DNA replication or microtubule polymerization.

Internalization efficiency is influenced by multiple factors including antigen density, antibody affinity, binding epitopes, and cell types. Different antibody clones against the same target may exhibit significant variations in internalization. Therefore, establishing reliable internalization evaluation methods early in ADC development is crucial for candidate screening and molecular optimization.

III. Structure and Preparation of DT3C Protein

DT3C is a genetically engineered fusion protein containing two functional modules. The first module derives from the catalytic domain (A chain) of diphtheria toxin (DT), which lacks receptor-binding capability but retains ADP-ribosyltransferase activity to inhibit protein synthesis by modifying elongation factor EF-2. The second module comprises the C1, C2, C3 domains of streptococcal protein G (Spg) that bind IgG Fc regions.

DT3C can be produced via prokaryotic expression systems (e.g., E. coli). The DT3C gene is cloned into expression vectors, transformed into host cells, and purified through affinity chromatography to obtain high-purity recombinant protein with excellent stability and bioactivity for rapid IgG binding.

IV. Principle of DT3C-Based Internalization Assay

The DT3C assay measures internalization efficiency through cytotoxicity readout. Antibodies are incubated with DT3C for 30 minutes to form mAb-DT3C complexes via Fc binding, mimicking ADC structures with DT3C replacing cytotoxic payloads.

When added to antigen-expressing tumor cells, internalized complexes release active DT domains through furin cleavage in the cytosol. The DT domain ADP-ribosylates EF-2, inhibiting protein synthesis and causing cell death. Cell viability assays (e.g., MTT, CCK-8) quantitatively reflect internalization efficiency—lower viability indicates higher internalization.

This functional assay closely aligns with ADC mechanisms and supports diverse IgG sources (human, mouse, rabbit, goat).

V. Applications in ADC Development

DT3C is widely used in ADC research for: Antibody screening—comparing internalization of candidate clones; Antody engineering—evaluating affinity maturation, humanization, or Fc modifications; and Target validation—assessing internalization across cell lines for indication selection.

Literature reports successful DT3C applications, including anti-Mucin 13 mAb screening for pancreatic ductal adenocarcinoma. Over 130 ADC-related patents cite DT3C, demonstrating its industry acceptance.

VI. Summary and Outlook

DT3C offers a simple, reliable, high-throughput internalization assay that aligns with ADC mechanisms, enabling early-stage screening of optimal antibodies. Future directions include developing fluorescent/luminescent DT3C variants for non-cytotoxic assays and expanding applications through fusion with other functional domains.

VII. DT3C (Diphtheria Toxin & spg 3C Domain) Protein Suppliers

Nanjing UA-Bio Technology Co., Ltd. has developed "DT3C (Diphtheria toxin & spg 3C domain) Protein, Corynephage beta", a high-quality recombinant reagent for targeted toxin research and protein fusion technologies. This fusion protein combines diphtheria toxin with spg 3C domain from Corynephage beta, maintaining full toxin activity and 3C protease specificity for immunotoxin construction, targeted drug development, and protein purification.

Nanjing UA-Bio specializes in core reagents for immunology, cell therapy, and drug discovery. For detailed specifications (Cat# UA070063) or technical inquiries, please contact us.